IBRX
The market liked the sneak peek
ImmunityBio didn’t wait for the full earnings confetti cannon. It dropped preliminary Q1 2026 product revenue of about $44.2 million, and the stock answered with a 7% jump. In biotech, that’s basically the market saying, “Okay, show us more.”
Why investors are paying attention
The big story here is Anktiva, ImmunityBio’s lead product and the engine behind the revenue surge. Product sales are expected to be up 168% year over year and 15% sequentially, which suggests the launch is still finding its groove rather than running out of steam.
That matters because biotech stocks often live or die by two things:
- whether a drug is actually getting adopted in the real world
- whether management can keep expanding the label so the party gets bigger
The next shoe: label expansion
ImmunityBio is also pushing Anktiva into more territory. The company recently resubmitted an FDA supplemental filing for broader bladder-cancer use, and it’s running studies in BCG-naïve NMIBC — a much larger patient pool than the current approved setting.
And it’s not stopping there. The company is also exploring Anktiva across a grab bag of tougher cancers, from NSCLC to pancreatic cancer and glioblastoma. That’s a lot of shots on goal, which is either exciting or very biotech, depending on your level of optimism.
Big picture
Today’s move is less about a one-day revenue beat and more about the market getting confirmation that Anktiva is doing what a good biotech asset is supposed to do: sell, scale, and keep opening new doors. If the adoption trend holds, IBRX may have a much bigger story ahead than just one strong quarter.